The key dates for this appraisal are:
Closing date for comments: 24/01/2018
Fourth appraisal committee meeting: 6 March 2018
Extavia (interferon beta 1b) is recommended as an option for treating multiple sclerosis, only if:
- the person has relapsing–remitting multiple sclerosis or
- the person has secondary progressive multiple sclerosis with continued relapses and
- the company provides it with the discount agreed in the patient access scheme.
Glatiramer acetate and the other beta interferons (Avonex, Betaferon, Plegridy and Rebif) are more expensive than Extavia, and the most likely cost-effectiveness estimates for these treatments compared with best supportive care are higher than what NICE normally considers acceptable. So, these treatments are not recommended for multiple sclerosis because they would not be a good use of limited NHS resources at their current prices.
So this would suggest that Merck, Biogen, Bayer and Teva have until March 2018 to reduce their price or its curtains.
2018 is shaping to be a year of a shake up in the UK,
What happens when generics small molecules arrive?
The end of the biologicals?